| Top Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > Inventory Management and Investment Portfolios |
|
Top Articles - Inventory Management and Investment Portfolios
Be it stocks, bonds, real estate, or business opportunities, anyone who invests in these entities understands the goal of the inves According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product tment; to gain the highest return possible with the lowest amount of risk. The method utilized by investment managers is to collec ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in t and analyze vast amounts of information. Everyday, these managers review, analyze, and eventually decide whether or not to invest lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. in an investment opportunity. This occurs thousands upon thousands of times each day with billions of dollars being exchanged. In here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe America alone, there is roughly $600 billion that is tied up in working capital and a large portion of that amount is inventory. Un d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ortunately, much of this inventory was purchased utilizing outdated concepts of planning inventory. For example, a typical inventor ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc y planner will only consider three or four variables when deciding on whether to invest in inventory such as weeks worth of supply, easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ABCD stratification, usage rates, etc. However, there are at least a dozen or more dynamic variables that impact inventory on a mo nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically thly basis. These variables include, minimum or maximum order quantities, freight policies, cost, lead time, previous demand, prese and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ nt demand, future demand, service level targets, reduction goals, cycle demand, etc. The list is ongoing and varies from one organi ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ation to the next. The point is, what if you learned that your 401k fund manager only reviewed two or three variables for managing ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a your investment? Would you feel confident in their ability to manage your money? Then why is it that many organizations accept the dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod current methods employed to manage such an enormous asset like inventory? To more strategically plan your inventory it is importa cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin t to consider why inventory exists in the first place. Distributors and manufactures are meeting customer demand (need) with supply tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen (product). In so doing the vendor expects to earn a return (profit) commensurate with the amount of risk. Does this sound familiar t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel with the expectation of an investment fund manager? Through the use of advanced inventory optimization, there is a better way to p ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust lan inventory that takes into account all dynamic variables that impact your inventory levels. This approach not only reduces the r y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products isk of your investment, but also improves your return through achieving higher service levels with a lower amount of inventory. Mos . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de of these projects are undertaken with a high probability of achieving an ROI within six to twelve months. Contact TCLogic for more elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Screening Job Applicants - What Really Goes On Behind Closed Doors? Video Marketing - What YouTube Can Do For Your Website
|